Summary of PolyPid's Q4 and Full Year 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Financials::

Research and Development (R&D) expenses: $6.2 million (down from $7 million in Q4 2024).

General and Administrative (G&A) expenses: $1.8 million (up from $1 million in Q4 2024).

Marketing and Business Development expenses: $0.6 million (up from $0.2 million in Q4 2024).

Net loss: $8.5 million or $0.41 per share (compared to a net loss of $8.5 million or $1.13 per share in Q4 2024).

Full Year 2025 Financials::

R&D expenses: $23.8 million (up from $22.8 million in 2024).

G&A expenses: $7.2 million (up from $4.3 million in 2024).

Marketing and Business Development expenses: $2 million (up from $0.9 million in 2024).

Net loss: $34.2 million or $2.09 per share (compared to a net loss of $29 million or $4.91 per share in 2024).

Cash position as of December 31, 2025: $12.9 million, with an additional $3.7 million raised from warrant exercises post-quarter.

2Strategic Updates and Business Highlights

Successfully completed the SHIELD II Phase III trial for D-PLEX100, achieving primary and key secondary endpoints, demonstrating a significant reduction in surgical site infections.

Received positive FDA feedback supporting a rolling NDA submission for D-PLEX100, expected to begin by the end of Q1 2026.

Advanced discussions with potential U.S. commercial partners, indicating strong interest in D-PLEX100's clinical profile.

Introduced Kynatrix, a new technology platform expanding beyond localized delivery of small molecules to address systemic therapeutic needs, including a long-acting GLP-1 Receptor Agonist program.

Appointed Brooke Story as Chairman of the Board, enhancing leadership for commercialization efforts.

3Forward Guidance and Outlook

2026 is anticipated to be transformative for PolyPid, with the rolling NDA submission and ongoing partnership discussions.

Existing cash resources are expected to fund operations into the second half of 2026, supporting significant upcoming milestones.

4Bad News, Challenges, or Points of Concern

The net loss increased year-over-year, indicating ongoing financial challenges as the company transitions from R&D to commercialization.

The need for successful partnership agreements and market access strategies remains critical, with potential delays in uptake post-approval.

The competitive landscape for surgical infection prevention and metabolic disease treatments may pose risks to market entry and share.

5Notable Q&A Insights

Management confirmed the initial label for D-PLEX100 will focus on preventing surgical site infections in abdominal colorectal surgery, with potential for future label expansion.

Discussions with the FDA indicated a favorable view of the SHIELD II trial data, which is crucial for NDA submission.

The company is focused on building awareness and preparing for market access, including health economics research and KOL engagement.

The Kynatrix platform is an evolution of existing technology, with ongoing R&D efforts leveraging past work to expedite future product development. Overall, PolyPid is positioned for significant developments in 2026, with a clear focus on regulatory progress and commercialization, despite ongoing financial losses and the challenges inherent in transitioning to a commercial entity.